CAPTRUST Financial Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $895K | Sell |
5,189
-89
| -2% | -$16.5K | ﹤0.01% | 1678 |
|
|
2025
Q4 | $1.05M | Sell |
5,278
-58
| -1% | -$10.5K | ﹤0.01% | 1475 |
|
|
2025
Q3 | $835K | Sell |
5,336
-80
| -1% | -$12.7K | ﹤0.01% | 1536 |
|
|
2025
Q2 | $822K | Sell |
5,416
-3,755
| -41% | -$501K | ﹤0.01% | 1453 |
|
|
2025
Q1 | $1.38M | Buy |
9,171
+2,750
| +43% | +$461K | ﹤0.01% | 1105 |
|
|
2024
Q4 | $1.19M | Sell |
6,421
-1,951
| -23% | -$376K | ﹤0.01% | 1152 |
|
|
2024
Q3 | $1.65M | Sell |
8,372
-989
| -11% | -$206K | ﹤0.01% | 938 |
|
|
2024
Q2 | $1.93M | Buy |
9,361
+830
| +10% | +$188K | 0.01% | 834 |
|
|
2024
Q1 | $2.31M | Sell |
8,531
-2,419
| -22% | -$578K | 0.01% | 749 |
|
|
2023
Q4 | $2.59M | Buy |
10,950
+1,778
| +19% | +$350K | 0.01% | 803 |
|
|
2023
Q3 | $1.8M | Buy |
9,172
+5,227
| +132% | +$1.07M | 0.01% | 902 |
|
|
2023
Q2 | $829K | Sell |
3,945
-718
| -15% | -$143K | ﹤0.01% | 1321 |
|
|
2023
Q1 | $941K | Sell |
4,663
-264
| -5% | -$59.8K | ﹤0.01% | 1074 |
|
|
2022
Q4 | $1.07M | Buy |
4,927
+1,175
| +31% | +$257K | 0.01% | 933 |
|
|
2022
Q3 | $738K | Buy |
3,752
+280
| +8% | +$60.4K | ﹤0.01% | 1072 |
|
|
2022
Q2 | $743K | Buy |
3,472
+524
| +18% | +$128K | ﹤0.01% | 974 |
|
|
2022
Q1 | $837K | Buy |
2,948
+113
| +4% | +$34.8K | 0.01% | 923 |
|
|
2021
Q4 | $1.07M | Sell |
2,835
-457
| -14% | -$178K | 0.01% | 790 |
|
|
2021
Q3 | $1.36M | Buy |
3,292
+76
| +2% | +$31.6K | 0.01% | 630 |
|
|
2021
Q2 | $1.19M | Sell |
3,216
-268
| -8% | -$89.5K | 0.01% | 654 |
|
|
2021
Q1 | $1.01M | Buy |
3,484
+1,697
| +95% | +$472K | 0.01% | 696 |
|
|
2020
Q4 | $446K | Sell |
1,787
-709
| -28% | -$169K | 0.01% | 875 |
|
|
2020
Q3 | $575K | Sell |
2,496
-26
| -1% | -$5.4K | 0.01% | 677 |
|
|
2020
Q2 | $443K | Buy |
2,522
+19
| +0.8% | +$3.03K | 0.01% | 749 |
|
|
2020
Q1 | $299K | Sell |
2,503
-132
| -5% | -$19.8K | 0.01% | 727 |
|
|
2019
Q4 | $406K | Buy |
2,635
+2,065
| +362% | +$286K | 0.01% | 756 |
|
|
2019
Q3 | $75K | Sell |
570
-7
| -1% | -$939 | ﹤0.01% | 863 |
|
|
2019
Q2 | $82K | Sell |
577
-9
| -2% | -$1.22K | ﹤0.01% | 817 |
|
|
2019
Q1 | $85K | Sell |
586
-26
| -4% | -$3.42K | ﹤0.01% | 743 |
|
|
2018
Q4 | $69K | Buy |
612
+308
| +101% | +$38.6K | ﹤0.01% | 681 |
|
|
2018
Q3 | $41K | Sell |
304
-86
| -22% | -$10.6K | ﹤0.01% | 811 |
|
|
2018
Q2 | $44K | Sell |
390
-6
| -2% | -$649 | ﹤0.01% | 710 |
|
|
2018
Q1 | $41K | Buy |
396
+184
| +87% | +$19.8K | ﹤0.01% | 655 |
|
|
2017
Q4 | $23K | Buy |
+212
| New | +$23.1K | ﹤0.01% | 744 |
|
Other funds holding CRL
VCM
VPM
CAPTRUST Financial Advisors's CRL Position: Q1 2026 in Review
CAPTRUST Financial Advisors reduced its Charles River Laboratories (CRL) stake by 1.7% in Q1 2026, selling an estimated $16.5K and leaving 5,189 shares worth $895K. The position accounts for ﹤0.01% of the portfolio, ranked #1678.
CAPTRUST Financial Advisors first reported a position in CRL in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.59M in Q4 2023. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- CAPTRUST Financial Advisors held 5,189 shares of Charles River Laboratories worth $895K as of Q1 2026.
- CAPTRUST Financial Advisors sold 89 Charles River Laboratories shares in Q1 2026, an estimated $16.5K.
- Charles River Laboratories made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1678 holding.
- CAPTRUST Financial Advisors first reported a position in Charles River Laboratories in Q4 2017 and has held it in 34 quarters since.
- CAPTRUST Financial Advisors's Charles River Laboratories position peaked at $2.59M in Q4 2023.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.